JP2023504914A5 - - Google Patents
Info
- Publication number
- JP2023504914A5 JP2023504914A5 JP2022534664A JP2022534664A JP2023504914A5 JP 2023504914 A5 JP2023504914 A5 JP 2023504914A5 JP 2022534664 A JP2022534664 A JP 2022534664A JP 2022534664 A JP2022534664 A JP 2022534664A JP 2023504914 A5 JP2023504914 A5 JP 2023504914A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- isvd
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025025563A JP2025081540A (ja) | 2019-12-09 | 2025-02-20 | Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962945391P | 2019-12-09 | 2019-12-09 | |
| US62/945,391 | 2019-12-09 | ||
| EP20305064 | 2020-01-27 | ||
| EP20305064.6 | 2020-01-27 | ||
| PCT/EP2020/085304 WO2021116182A1 (en) | 2019-12-09 | 2020-12-09 | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025025563A Division JP2025081540A (ja) | 2019-12-09 | 2025-02-20 | Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504914A JP2023504914A (ja) | 2023-02-07 |
| JP2023504914A5 true JP2023504914A5 (cg-RX-API-DMAC7.html) | 2023-10-17 |
| JP7641968B2 JP7641968B2 (ja) | 2025-03-07 |
Family
ID=73793214
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022534664A Active JP7641968B2 (ja) | 2019-12-09 | 2020-12-09 | Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
| JP2025025563A Pending JP2025081540A (ja) | 2019-12-09 | 2025-02-20 | Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025025563A Pending JP2025081540A (ja) | 2019-12-09 | 2025-02-20 | Il-13およびtslpを標的化する免疫グロブリン単一可変ドメインを含むポリペプチド |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20210188965A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4072674A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7641968B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102984686B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114980974A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020400938A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022010223A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3163910A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2022008813A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL293548A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022007035A (cg-RX-API-DMAC7.html) |
| MY (1) | MY208649A (cg-RX-API-DMAC7.html) |
| TW (2) | TWI861302B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021116182A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017189805A1 (en) | 2016-04-27 | 2017-11-02 | Abbvie Inc. | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| WO2022063984A1 (en) * | 2020-09-25 | 2022-03-31 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and ox40l |
| CA3217029A1 (en) * | 2021-05-30 | 2022-12-08 | Biolojic Design Ltd. | Engineered dual binding antibodies and uses thereof |
| KR20250025381A (ko) | 2022-06-17 | 2025-02-21 | 아포지 바이오로직스, 인크. | 인터류킨 13에 결합하는 항체 및 사용 방법 |
| WO2024017915A1 (en) * | 2022-07-18 | 2024-01-25 | Ablynx N.V. | Cx3cr1-binding compounds, uses thereof and related methods |
| CN118005784A (zh) | 2022-11-08 | 2024-05-10 | 上海洛启生物医药技术有限公司 | 抗il-13长效纳米抗体序列及其应用 |
| US20240415974A1 (en) | 2022-12-23 | 2024-12-19 | Ablynx N.V. | Protein-based conjugation carriers |
| IL322519A (en) | 2023-02-17 | 2025-10-01 | Ablynx Nv | Polypeptides that bind to the neonatal fc receptor |
| AU2024247861A1 (en) | 2023-03-24 | 2025-11-06 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| EP4435005A1 (en) | 2023-03-24 | 2024-09-25 | Sanofi | Asthma treatment by blocking il-13 and tslp |
| EP4731663A2 (en) * | 2023-06-22 | 2026-04-29 | Paragon Therapeutics, Inc. | Antibodies that bind interleukin 13 and tslp or tslpr and methods of use |
| AR133647A1 (es) | 2023-08-25 | 2025-10-22 | Proteologix Us Inc | Constructos de anticuerpos multiespecíficos anti-il-13 y usos de los mismos |
| AR134101A1 (es) * | 2023-10-12 | 2025-12-03 | Innovent Biologics Suzhou Co Ltd | Anticuerpos anti-tslp y usos de los mismos |
| WO2025209486A1 (en) * | 2024-04-02 | 2025-10-09 | Keymed Biosciences (Chengdu) Co., Ltd. | Antibodies targeting il-13 and tslp and uses thereof |
| WO2026041740A1 (en) | 2024-08-21 | 2026-02-26 | Sanofi | Treatment of high-risk asthma by blocking il-13 and tslp |
| WO2026055143A2 (en) * | 2024-09-03 | 2026-03-12 | Attovia Therapeutics, Inc. | Il13-binding polypeptides and uses thereof |
| WO2026067440A1 (zh) * | 2024-09-29 | 2026-04-02 | 四川科伦博泰生物医药股份有限公司 | Tslp/il-13双特异性抗体及其用途 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69334275D1 (de) | 1992-08-21 | 2009-05-20 | Univ Bruxelles | Immunoglobuline ohne Leichtkette |
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (da) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalente antigenbindende proteiner |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| GB0407315D0 (en) * | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| AU2007237501A1 (en) | 2006-04-14 | 2007-10-25 | Ablynx N.V. | DP-78-like nanobodies |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン.ヴェー. | Il−6媒介性シグナル伝達に関連する疾患及び障害の治療のための、il−6rに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US20100113339A1 (en) * | 2006-09-08 | 2010-05-06 | Ablynx N. V. | Serum albumin binding proteins with long half-lives |
| AR064333A1 (es) * | 2006-12-14 | 2009-04-01 | Schering Corp | Anticuerpo anti-tslp de diseno |
| CA2744588A1 (en) * | 2008-11-26 | 2010-06-03 | Glaxo Group Limited | Ligands that bind il-13 |
| CA3141978A1 (en) | 2011-06-23 | 2012-12-27 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| LT3466972T (lt) | 2011-06-23 | 2026-06-25 | Ablynx Nv | Serumo albuminą surišantys baltymai |
| LT3248986T (lt) | 2014-05-16 | 2022-03-25 | Ablynx Nv | Imunoglobulino kintami domenai |
| CN107428828A (zh) * | 2015-03-11 | 2017-12-01 | 葛兰素史密斯克莱知识产权发展有限公司 | Tslp结合蛋白 |
| HUE057241T2 (hu) | 2015-11-13 | 2022-04-28 | Ablynx Nv | Javított, szérumalbumint kötõ immunoglobulin variábilis domének |
| US10544222B2 (en) * | 2015-11-18 | 2020-01-28 | Merck Sharp & Dohme Corp. | PD1/CTLA4 binders |
| AU2016357460B2 (en) | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| CA3006398A1 (en) * | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| US11248057B2 (en) * | 2016-03-07 | 2022-02-15 | Vib Vzw | CD20 binding single domain antibodies |
| US11840569B2 (en) | 2016-11-16 | 2023-12-12 | Ablynx N.V. | T cell recruiting polypeptides capable of binding CD123 and TCR alpha/beta |
| WO2018104444A1 (en) | 2016-12-07 | 2018-06-14 | Ablynx Nv | Improved serum albumin binding immunoglobulin single variable domains |
| EP3571224B1 (en) | 2017-01-17 | 2024-08-07 | Ablynx NV | Improved serum albumin binders |
| EP4442709A3 (en) | 2017-01-17 | 2024-12-25 | Ablynx NV | Improved serum albumin binders |
| KR20260100427A (ko) * | 2018-03-28 | 2026-06-29 | 오리오니스 바이오사이언시즈 인코포레이티드 | 이작용성 단백질 및 이의 작제물 |
| CN112687354B (zh) * | 2019-01-29 | 2022-07-12 | 杭州纽安津生物科技有限公司 | 针对靶向药物PI3K、AKT、mTOR通路的激酶抑制剂的多肽疫苗组合及其设计方法 |
| CN114980974A (zh) | 2019-12-09 | 2022-08-30 | 艾伯霖克斯公司 | 含靶向il-13和tslp的免疫球蛋白单可变结构域的多肽 |
| AR120698A1 (es) | 2019-12-09 | 2022-03-09 | Ablynx Nv | Polipéptidos que comprenden dominios variables únicos de inmunoglobulina que se dirigen a il-13 y tslp |
-
2020
- 2020-12-09 CN CN202080085549.9A patent/CN114980974A/zh active Pending
- 2020-12-09 IL IL293548A patent/IL293548A/en unknown
- 2020-12-09 JP JP2022534664A patent/JP7641968B2/ja active Active
- 2020-12-09 TW TW109143498A patent/TWI861302B/zh active
- 2020-12-09 AU AU2020400938A patent/AU2020400938A1/en active Pending
- 2020-12-09 BR BR112022010223A patent/BR112022010223A2/pt unknown
- 2020-12-09 MX MX2022007035A patent/MX2022007035A/es unknown
- 2020-12-09 TW TW113137609A patent/TW202530257A/zh unknown
- 2020-12-09 WO PCT/EP2020/085304 patent/WO2021116182A1/en not_active Ceased
- 2020-12-09 US US17/115,906 patent/US20210188965A1/en not_active Abandoned
- 2020-12-09 KR KR1020227023385A patent/KR102984686B1/ko active Active
- 2020-12-09 EP EP20823785.9A patent/EP4072674A1/en active Pending
- 2020-12-09 MY MYPI2022002971A patent/MY208649A/en unknown
- 2020-12-09 CA CA3163910A patent/CA3163910A1/en active Pending
-
2021
- 2021-11-19 US US17/530,850 patent/US12492248B2/en active Active
- 2021-11-19 US US17/530,727 patent/US12384840B2/en active Active
- 2021-11-19 US US17/530,800 patent/US11840566B2/en active Active
-
2022
- 2022-06-24 CO CONC2022/0008813A patent/CO2022008813A2/es unknown
-
2025
- 2025-02-20 JP JP2025025563A patent/JP2025081540A/ja active Pending
- 2025-11-12 US US19/386,343 patent/US20260152549A1/en active Pending